<DOC>
	<DOCNO>NCT02863926</DOCNO>
	<brief_summary>Patients schedule knee amputation ( BKA ) receive bone marrow cell ( cBMA ) inject IM leg proximal BKA index limb prevent ischemic wound complication surgery .</brief_summary>
	<brief_title>Use Autologous Concentrated Bone Marrow Aspirate Preventing Wound Complications Below Knee Amputation ( BKA )</brief_title>
	<detailed_description>Patients schedule BKA receive bone marrow cell concentrate via MarrowStim device ( cBMA ) inject IM 25 site leg proximal BKA index limb prevent ischemic wound complication surgery . cBMA control ( 0.9 % NaCl ) inject ATM point amputation 4 select site analytical purpose . Patients scheduled amputation Days 7 , 14 , 21 post injection . Safety evaluate review treatment related adverse event ( AE ) 12-month follow-up period . The investigator compare rate wind complication conversion BKA AKA historical control institution ass trend therapeutic efficacy . Patients undergo BKA injection site harvest time . Immunohistochemical staining ( IHC ) determine capillary density local host immune response . Angiogenic inflammatory cytokine quantify use multiplex array system quantitative polymerase chain reaction ( PCR ) .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>1 . Be ≥ 40 ≤80 year age . 2 . Patients require knee amputation , determine independent vascular specialist , rest pain , nonsuppurative gangrene , ulceration due limb ischemia . 3 . Resting Ankle Brachial Index &lt; 0.55 TBI &lt; 0.40 . 4 . Ulceration gangrene distal malleoli ( allow adequate length ATM 4 injection 4 cm . apart ) 5 . Subjects bilirubin range 0.3 1.9 mg/dL 6 . BKA safely perform 30 day screen , determine independent vascular orthopedic surgeon . This information document subject ' case report form ( CRFs ) . 7 . Females childbearing potential must willing use one form birth control duration study . Female participant must undergo blood urine pregnancy test screening . 1 . Evidence infection . Suppurative gangrene : purulence emanate gangrenous area , without compression . Spreading cellulitis : proximal progression erythema wound within 24 hour . Systemic manifestation infection : WBC &gt; 11.5k ( antibiotic therapy &gt; 24 hour ) , increase oxygen requirement pulmonary failure , pressor support , change creatinine &gt; 50 % baseline 2 . Patients pregnant , plan become pregnant next 12 month , lactate . 3 . Significant hepatic dysfunction ( ALT AST great 2 time normal ) . 4 . CHF hospitalization within last 1 month prior enrollment . * 5 . Acute coronary syndrome ( ACS ) last 1 month prior enrollment . * 6 . HIV positive , active HBV HCV . 7 . History cancer within last 5 year , except basal cell skin carcinoma 8 . Any bleeding diathesis define INR ≥ 2.0 ( anticoagulation therapy ) history platelet count le 70,000 hemophilia . 9 . Inability provide write informed consent due cognitive language barrier ( interpreter permit ) . 10 . Concurrent enrollment another clinical investigative trial . 11 . Any condition require immunosuppressant medication ( e.g. , treatment organ transplant , psoriasis , Crohn 's disease , alopecia areata ) . 12 . Presence clinical condition opinion PI sponsor make patient suitable participate trial . As defined standard definition CHF ACS American Heart Association .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>BKA</keyword>
	<keyword>amputation</keyword>
	<keyword>MarrowStim</keyword>
	<keyword>knee amputation</keyword>
	<keyword>wound complication</keyword>
	<keyword>vascular disease</keyword>
	<keyword>critical limb ischemia</keyword>
	<keyword>peripheral artery disease</keyword>
	<keyword>AKA</keyword>
	<keyword>stem cell</keyword>
	<keyword>bone marrow</keyword>
</DOC>